Acumen Pharmaceuticals, Inc. Announces Annual Meeting of Stockholders on June 4, 2024

TL;DR

<b>Acumen Pharmaceuticals will hold its Annual Meeting of Stockholders on June 4, 2024, to elect directors and ratify auditors, with proxy materials available online.</b>

AI Summary

Acumen Pharmaceuticals, Inc. (ABOS) filed a Proxy Statement (DEF 14A) with the SEC on April 22, 2024. Acumen Pharmaceuticals will hold its Annual Meeting of Stockholders on June 4, 2024, at 11:00 a.m. Eastern Time via live video webcast. The meeting agenda includes the election of two Class III directors, Daniel O'Connell and Nathan Fountain, M.D., for terms until the 2027 Annual Meeting. Stockholders will vote to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. Proxy materials will be provided via the Internet, with a Notice of Internet Availability mailed on or about April 22, 2024. The record date for determining stockholders entitled to vote at the meeting is April 15, 2024.

Why It Matters

For investors and stakeholders tracking Acumen Pharmaceuticals, Inc., this filing contains several important signals. The company is leveraging internet delivery of proxy materials to reduce costs and environmental impact, a common practice for public companies. The election of directors and ratification of auditors are standard agenda items for annual shareholder meetings, indicating routine corporate governance.

Risk Assessment

Risk Level: low — Acumen Pharmaceuticals, Inc. shows low risk based on this filing. The filing is a routine proxy statement with no significant new financial or strategic information, indicating low immediate risk.

Analyst Insight

Stockholders should review the director nominees and auditor ratification to make informed voting decisions at the upcoming Annual Meeting.

Key Numbers

• June 4, 2024 — Annual Meeting Date (Date of the Annual Meeting of Stockholders)
• 2027 — Director Term End (Term end year for elected directors)
• December 31, 2024 — Fiscal Year End (Fiscal year for which auditors are being ratified)
• April 22, 2024 — Notice Mailing Date (Expected date for mailing Notice of Internet Availability of Proxy Materials)
• April 15, 2024 — Record Date (Date to determine stockholders eligible to vote)

Key Players & Entities

• Acumen Pharmaceuticals, Inc. (company) — Registrant
• Daniel O'Connell (person) — Director nominee
• Nathan Fountain, M.D. (person) — Director nominee
• Ernst & Young LLP (company) — Independent registered public accounting firm
• June 4, 2024 (date) — Annual Meeting date
• April 22, 2024 (date) — Mailing date for Notice of Internet Availability
• April 15, 2024 (date) — Record date for Annual Meeting

FAQ

Risk Factors

• Reliance on Internet Availability of Proxy Materials [low — operational]: The company is providing proxy materials via the internet to reduce costs and environmental impact, which could affect stockholder access if they are not comfortable with online access.

Key Dates

• 2024-06-04: Annual Meeting of Stockholders — To elect directors and ratify auditors.
• 2024-04-22: Mailing of Notice of Internet Availability — Informs stockholders how to access proxy materials online.
• 2024-04-15: Record Date — Determines which stockholders are eligible to vote at the Annual Meeting.

Filing Documents

• def14a.htm (DEF 14A) — 533KB
• acumenproxycardinbw001.jpg (GRAPHIC) — 190KB
• acumenproxycardinbw002.jpg (GRAPHIC) — 97KB
• image_0.jpg (GRAPHIC) — 27KB
• picture1.jpg (GRAPHIC) — 8KB
• picture2.jpg (GRAPHIC) — 3KB
• 0001576885-24-000055.txt (&nbsp;) — 980KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 21 Delinquent Section 16(A) Reports 23 Report of the Audit Committee of the Board of Directors 24

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 25 Summary Compensation Table 25 Director Compensation 31 Equity Compensation Plan Information 32 TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION 34 Related Person Transactions Policy And Procedures 34 Certain Related Person Transactions 34 HOUSEHOLDING OF PROXY MATERIALS 36 OTHER MATTERS 36 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS April 22, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a notice regarding the availability of proxy materials on the Internet Pursuant to rules adopted by the Securities and Exchange Commission (the " SEC "), we have elected to provide access to our proxy materials over the Internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the " Notice ") because the Board of Directors (the " Board ") of Acumen Pharmaceuticals, Inc. (sometimes referred to as the " Company " or " Acumen ") is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders (the " Annual Meeting "), including at any adjournments or postponements of the meeting. The Notice, the Notice of Annual Meeting of Stockholders, this proxy statement (the " Proxy Statement "), the proxy card or voting instruction form, and our 2023 Annual Report (collectively, the " Proxy Materials ") are available to stockholders on the website referred to in the Notice. All stockholders will also have the ability to request to receive a printed set of the Proxy Materials. The Notice will provide instructions as to how a stockholder of record may access and review the Proxy Materials on the website referred to in the Notice or, alternatively, how to request that a copy of the Proxy Materials, including a proxy card, be sent by mail or email to the stockholder of record. The Notice will also provide voting instructions. Please note that, while our Proxy Materials are available at the website referenced in the Notice, and our Notice,

View Full Filing

View this DEF 14A filing on SEC EDGAR